Design of VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1): A double-blind, randomized placebo-controlled trial of COVID-19 convalescent plasma in hospitalized patients with early respiratory compromise
Background: Effective therapeutics for severe acute respiratory syndrome CoronaVirus-2 (SARS-CoV-2) infection are evolving. Under Emergency Use Authorization, COVID-19 convalescent plasma (CCP) was widely used in individuals hospitalized for COVID-19, but few randomized controlled trials supported i...
Main Authors: | Edward N. Janoff, Sheldon T. Brown, Ilana Belitskaya-Levy, Jeffrey L. Curtis, Robert A. Bonomo, Elliott K. Miller, Alexa M. Goldberg, Lisa Zehm, Ashlea Wills, Caitlin Hutchinson, Larry J. Dumont, Theresa Gleason, Mei-Chiung Shih |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-10-01
|
Series: | Contemporary Clinical Trials Communications |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2451865423001369 |
Similar Items
-
Comparing SARS-CoV-2 neutralizing antibody levels in convalescent unvaccinated, convalescent vaccinated, and naive vaccinated subjects
by: Latha Dulipsingh, et al.
Published: (2023-06-01) -
Korean version of the convalescence and recovery evaluation: translation and linguistic validation
by: Hyeong Dong Yuk, et al.
Published: (2020-12-01) -
The effect of convalescent plasma on the treatment of COVID-19 patients in Ardabil, Iran
by: Effat Iranijam, et al.
Published: (2022-01-01) -
Convalescent plasma therapy in COVID-19
by: Ayse Uysal, et al.
Published: (2022-06-01) -
Use of convalescent plasma to treat COVID-19: case studies
by: Stéphani Caroline Beneti, et al.
Published: (2023-07-01)